Neeta Pandit-Taskar

May 24, 2024 | jnm.snmjournals.org | Neeta Pandit-Taskar |Joseph O’Donoghue |Dushen Chetty |Steven Max

Anterior and posterior planar 111In whole-body images were obtained immediately after study agent administration (0–4 h) and on day 2 (24 ± 6 h), days 3–4 (42–78 h), and days 6–9 (114–198 h). A SPECT/CT scan from the inferior portion of the lungs to the kidneys was performed at one or more of these time points. For all time points except 0–4 h, participants were instructed to void urine before imaging.

Mar 21, 2024 | jnm.snmjournals.org | Samuel Cytryn |Neeta Pandit-Taskar |Melissa Lumish |Steven B. Maron

MATERIALS AND METHODSThis was a single-institution prospective pilot open-label microdose PET evaluating the PD-L1–targeting radiotracer 18F-BMS-986229 with PET imaging in 10 patients with GEC between February 3, 2020 and February 2, 2022. Ten (100%) patients had adenocarcinoma, 7 (70%) had metastatic disease, and 3 (30%) had received prior treatment at the time of PD-L1 PET imaging, including 2 with PD-1 inhibitors (Table 1). The median PD-L1 CPS was 10 (interquartile range, 5–20).